John Newman is ranked #1668 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

John Newman

Q: How accurate are John Newman's stock ratings?

About 56% of John's ratings were profitable over a one-year hold, with an average return of +2.7% per rating, measured by 13Foresight from historical prices.

Canaccord Genuity

Wall Street Analyst

★★★☆☆

#1668

on 13Foresight · ranked by our own returns

56%

Success Rate

+2.7%

Average Return

48 of 86 calls profitable · -0.8% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 56% of John Newman's ratings turned a profit when each position was held for 1 year — averaging +2.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

168 Buy 7 Hold 0 Sell

John's Stock Coverage 51 ratings · 2026-09-02

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
CMPX Compass Therapeutics	Sep 01, 2026	BUY	Strong Buy +306.6% avg upside 20 analysts	$7.00 203.05% Upside	·	·
BNTX BioNTech SE	Aug 31, 2026	BUY	Strong Buy +32.4% avg upside 26 analysts	$136.00 33.46% Upside	·	·
KZIA Kazia Therapeutics	Aug 31, 2026	BUY	Strong Buy +103.5% avg upside 8 analysts	$29.00 129.68% Upside	-8.3%	·
ACET Adicet Bio	Aug 26, 2026	BUY	Strong Buy +172.2% avg upside 14 analysts	$18.00 94.36% Upside	+1.2%	·
TYRA Tyra Bioscience	Aug 25, 2026	BUY	Strong Buy +76.8% avg upside 17 analysts	$50.00 97.63% Upside	-6.6%	·
INCY Incyte	Aug 21, 2026	BUY	Buy -13.2% avg upside 48 analysts	$152.00 21.58% Upside	-2.2%	·
MRKR Marker Therapeutics	Aug 17, 2026	BUY	Strong Buy +1022.2% avg upside 9 analysts	$8.00 515.45% Upside	+14.7%	·
CADL Candel Therapeutics	Aug 13, 2026	BUY	Strong Buy +42.8% avg upside 11 analysts	$25.00 94.55% Upside	+10.8%	·
ATRA Atara Biotherapeutics	Aug 13, 2026	BUY	Buy +99.9% avg upside 18 analysts	$13.00 44.04% Upside	+8.1%	·
ALLO Allogene Therapeutics	Aug 13, 2026	BUY	Strong Buy +674.7% avg upside 28 analysts	$14.00 605.29% Upside	+4.8%	·
BBOT BridgeBio Oncology Therapeutics	Aug 12, 2026	BUY	Strong Buy +183.8% avg upside 11 analysts	$23.00 160.72% Upside	-7.2%	·
TNGX Tango Therapeutics	Aug 12, 2026	BUY	Strong Buy +76.4% avg upside 15 analysts	$46.00 105.91% Upside	-12.7%	·
DCTH Delcath Systems	Aug 11, 2026	BUY	Strong Buy +33.9% avg upside 11 analysts	$21.00 28.05% Upside	-5.1%	·
MCRB Seres Therapeutics	Aug 06, 2026	BUY	Buy +217.4% avg upside 11 analysts	$22.00 324.65% Upside	+2.7%	·
LCTX Lineage Therap	Aug 06, 2026	BUY	Strong Buy +408.7% avg upside 16 analysts	$9.00 733.30% Upside	-1.8%	·
RLAY Relay Therapeutics	Aug 06, 2026	BUY	Strong Buy +20.4% avg upside 21 analysts	$29.00 56.75% Upside	-6.9%	·
XNCR Xencor	Aug 05, 2026	BUY	Strong Buy +25.6% avg upside 27 analysts	$38.00 36.16% Upside	+31.4%	·
REGN Regeneron	Jul 22, 2026	BUY	Strong Buy -5.0% avg upside 58 analysts	$875.00 6.26% Upside	+22.9%	·
ONCY Oncolytics Biotech	Nov 12, 2024	BUY	Strong Buy +679.1% avg upside 12 analysts	$5.00 495.18% Upside	+1.8%	·
IRD Opus Genetics	Nov 12, 2024	BUY	Strong Buy +160.1% avg upside 25 analysts	$10.00 161.15% Upside	+68.4%	·
PTN Palatin Technologies	Oct 01, 2024	BUY	Strong Buy +917.7% avg upside 4 analysts	$300.00 2499.59% Upside	-82.2%	·
RNAC Cartesian Therapeutics	Aug 08, 2024	BUY	Strong Buy +240.1% avg upside 19 analysts	$43.00 362.33% Upside	-18.2%	·
AGIO Agios Pharma	Feb 16, 2022	BUY	Strong Buy +81.4% avg upside 29 analysts	$44.00 28.64% Upside	-12.7%	·
CARM Carisma Therapeutics	Aug 17, 2021	BUY	Buy +288361.6% avg upside 11 analysts	$3.00 299899.96% Upside	·	·
HK:0013 HUTCHMED (China)	May 26, 2021	BUY	Buy +519.6% avg upside 6 analysts	$352.77 1743.13% Upside	·	·
BDSX Biodesix	May 12, 2021	BUY	Strong Buy +38.3% avg upside 9 analysts	$31.00 23.68% Upside	-87.7%	·
KLDO Kaleido Biosciences	May 04, 2021	BUY	Buy +260749900.0% avg upside 5 analysts	$19.00 18999899.90% Upside	·	·
HCM HUTCHMED	May 03, 2021	BUY	Strong Buy +157.7% avg upside 9 analysts	$45.00 277.82% Upside	-53.4%	·
RNTX Rein Therapeutics	Mar 25, 2021	BUY	Strong Buy +1097.3% avg upside 6 analysts	$5.00 564.31% Upside	·	·
TSE:PRN Profound Medical	Mar 09, 2020	BUY	Strong Buy +101.0% avg upside 11 analysts	$13.86 46.79% Upside	+73.8%	·
ALDX Aldeyra Therapeutics	Jun 26, 2019	BUY	Strong Buy +974.5% avg upside 21 analysts	$20.00 1242.26% Upside	-31.0%	·
MTVA MetaVia	Aug 13, 2018	BUY	Strong Buy +1627.9% avg upside 13 analysts	$6.00 248.91% Upside	·	·
XENE Xenon	Jun 27, 2017	BUY	Strong Buy +3.5% avg upside 28 analysts	$5.00 91.67% Downside	+163.3%	·
AUPH Aurinia Pharmaceuticals	Mar 10, 2017	BUY	Strong Buy -1.0% avg upside 12 analysts	$10.00 37.68% Downside	-34.8%	·
CBIO Crescent Biopharma	Mar 01, 2017	BUY	Strong Buy +24.3% avg upside 17 analysts	$12.00 32.98% Downside	·	·
IMUX Immunic	Dec 30, 2016	BUY	Strong Buy +159.4% avg upside 22 analysts	$10.00 31.49% Downside	·	·
DARE Daré Bioscience	Nov 09, 2016	BUY	Strong Buy +1638.4% avg upside 14 analysts	$60.00 7690.23% Upside	·	·
LPCN Lipocine	Oct 11, 2016	BUY	Strong Buy +683.8% avg upside 4 analysts	$15.00 552.21% Upside	·	·
ZVRA Zevra Therapeutics	Aug 10, 2016	BUY	Strong Buy +82.3% avg upside 15 analysts	$34.00 181.95% Upside	-20.6%	·
SVRA Savara	Jul 26, 2016	BUY	Strong Buy +61.0% avg upside 17 analysts	$3.00 43.95% Downside	·	·
GEO Geo Group	Jun 13, 2016	HOLD	Strong Buy +26.2% avg upside 11 analysts	$90.00 194.76% Upside	+54.8%	·
RCKT Rocket Pharmaceuticals	May 13, 2016	BUY	Buy +334.7% avg upside 30 analysts	$30.00 704.37% Upside	-81.8%	·
ZG Zillow Group Class A	May 02, 2016	BUY	Buy +62.9% avg upside 46 analysts	$26.00 24.33% Downside	+51.2%	·
MU Micron	Mar 31, 2016	BUY	Strong Buy +6.2% avg upside 53 analysts	$18.00 98.06% Downside	·	·
TLPH Talphera	Mar 09, 2015	HOLD	Buy +298.4% avg upside 15 analysts	$6.00 408.54% Upside	·	·
JAZZ Jazz Pharmaceuticals	Mar 03, 2015	BUY	Strong Buy -1.8% avg upside 35 analysts	$201.00 17.54% Downside	-28.8%	·
RMTI Rockwell Med	Jan 07, 2015	BUY	Hold +69.5% avg upside 11 analysts	$24.00 198.30% Upside	·	·
ARCT Arcturus Therapeutics	Oct 07, 2014	HOLD	Buy +85.8% avg upside 36 analysts	$9.00 44.61% Downside	-9.2%	·
BIIB Biogen	Dec 20, 2011	BUY	Strong Buy +16.4% avg upside 52 analysts	$127.00 41.20% Downside	+36.6%	·
MNKD MannKind	Mar 15, 2010	SELL	Buy +75.7% avg upside 22 analysts	$5.00 25.59% Upside	+52.0%	·
BC Brunswick	Jun 10, 2009	SELL	Buy +9.6% avg upside 32 analysts	—	·	·

🔒 46 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

John Newman — Frequently Asked Questions

How accurate are John Newman's stock ratings?

Based on the calls 13Foresight could measure, about 56% of John's ratings were profitable over a one-year hold, with an average return of +2.7% per rating, or -0.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is John ranked on 13Foresight?

John Newman is currently ranked #1668 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does John cover?

John most recently has ratings on CMPX, BNTX, KZIA, ACET, TYRA, INCY, MRKR, CADL, ATRA, ALLO, BBOT, TNGX and 39 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

John Newman

Rating Distribution

Welcome to 13Foresight!